ImmuneOnco Biopharmaceuticals (Shanghai) Inc 2025 Annual Report with Sustainability Disclosures
Company: ImmuneOnco Biopharmaceuticals (Shanghai) Inc
Sector: Manufacturing
Country: China
Year: 2025
Type: Annual Report with Sustainability Disclosures
Pages: 190
The report describes the company's 2025 sustainability performance across environmental, governance and workforce priorities. Total GHG emissions were 2,108.69 tCO2e, including 0.07 tCO2e of Scope 1, 1,675.19 tCO2e of Scope 2 and 433.43 tCO2e of Scope 3 emissions. The company reported zero incidents of corruption and fraud and maintained a workforce of 202 employees, of whom 64% were female. It also describes Board-led ESG oversight, climate-risk management and employee-focused health, safety and development initiatives.
Reporting standards, commitments and assurance details are available with a free account.
Data Services
From bulk PDFs to structured indicators and machine-readable documents.